# LaNova Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lanova-medicines

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.lanovamedicines.com
- Total disclosed funding: $42M
- Latest round: Series C (Oct 18, 2024)
- Investors on record: 12

## About

Based in Shanghai, China, and founded in 2019, LaNova Medicines operates as a pharmaceutical company that focuses on the research and development of clinical-stage innovative drugs. It was recognized as the National High-tech Enterprise. The company's R&D team has an average of more than 15 years of pharmaceutical R&D experience in the fields of immunology and oncology. It cooperated with AstraZeneca, TopAlliance, and other enterprises. The company's LM-302 antibody-drug conjugate project acquired China's NMPA IND approval in 2021. In May 2022, it reached an overseas exclusive licensing cooperation with Turning Point, USA, on the LM-302 project. The company focuses on the research and development of monoclonal anti-tumor drugs that target GPCR and multiple transmembrane proteins. It has an antibody discovery platform, a next-generation ADC technology platform, and an immune bridging multi-specific antibody platform. The targeted antibody discovery platform can screen monoclonal antibodies targeting GPCRs and multiplexed transmembrane proteins. It has multiple product pipelines, including LM-061, LM-102, LM-302, etc. The company generates revenue by providing monoclonal anti-tumor drugs. In October 2024, LaNova Medicines closed a series C1 funding led by Sino Biopharmaceutical Limited. In July 2025, Sino Biopharmaceutical Limited, a portfolio company of Goldman Sachs Asset Management, agreed to acquire the rest of 95.09% stake in LaNova Medicines at nearly USD 951 million.

## Funding rounds

- Series C, Oct 18, 2024, $42M — Qiming Venture Partners, Sino Biopharmaceutical Limited, Pudong Venture Capital, Shanghai Healthcare Capital, Zhangjiang Haoheng Capital
- Series B, Jun 28, 2022 — Qiming Venture Partners, Summer Capital, Shanghai Healthcare Capital, Taikun Fund
- Series A, Jan 22, 2021 — Qiming Venture Partners, YF Capital, TF Capital, Tsing Song Capital, Shangrun Investment
- Angel, Dec 17, 2019 — Tigermed

## Investors

- Tigermed (https://capitalatlas.ai/funds/tigermed) — Angel
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B, Series C
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series A
- TF Capital — Series A
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A
- Shangrun Investment (https://capitalatlas.ai/funds/shangrun-investment) — Series A
- Summer Capital — Series B
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series B, Series C
- Taikun Fund — Series B
- Sino Biopharmaceutical Limited — Series C
- Pudong Venture Capital (https://capitalatlas.ai/funds/pudong-venture-capital) — Series C
- Zhangjiang Haoheng Capital (https://capitalatlas.ai/funds/zhangjiang-haoheng-capital) — Series C